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My professional journey to understand the glucose homeostasis began in the 1990s, starting from cloning of the promoter region 
of glucose transporter type 2 (GLUT2) gene that led us to establish research foundation of my group. When I was a graduate stu-
dent, I simply thought that hyperglycemia, a typical clinical manifestation of type 2 diabetes mellitus (T2DM), could be caused by 
a defect in the glucose transport system in the body. Thus, if a molecular mechanism controlling glucose transport system could 
be understood, treatment of T2DM could be possible. In the early 70s, hyperglycemia was thought to develop primarily due to a 
defect in the muscle and adipose tissue; thus, muscle/adipose tissue type glucose transporter (GLUT4) became a major research 
interest in the diabetology. However, glucose utilization occurs not only in muscle/adipose tissue but also in liver and brain. Thus, 
I was interested in the hepatic glucose transport system, where glucose storage and release are the most actively occurring. 
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INTRODUCTION
In β-cells of pancreas and liver, glucose transport machinery 
consists of glucose transporter type 2 (GLUT2) and glucoki-
nase (Gck), which is also called a glucose sensor [1]. But in the 
1980s, the mechanism of the regulation of gene expression of 
hepatic glucose transport system in the insulin resistant, dia-
betic states was largely unknown. Thus, we started to clone up-
stream regions (promoters) of GLUT2, Gck, and glucose-6- 
phosphatase (G6Pase) and searched for potential trans-acting 
factors regulating the expression of these genes. In this review, 
I will introduce my research path which has mainly focused on 
the characterization of the transcriptional network of genes in-
volved in the glucose homeostasis. 
STARTING FROM RAT GLUT2 PROMOTER
In the 1990s, cloning of genes with upstream regulatory ele-
ments was the mainstream biochemistry field. Because it was 
the previous era of the Genome Project we had to manually se-
quence a lot of short gene fragments using Sanger’s dideoxy 
method to clone the whole rat GLUT2 gene, which was labori-
ous and time consuming. Dr. Gil-Soo Han, my first research 
associate, started the project, but left my Lab in 1993 before the 
work was completed. So, we had to determine sequence of 
exon 1 with 5´-flanking region. Repeated screenings of lambda 
phage clones finally revealed the exon 1 and upstream se-
quences, and furthermore, using rapid amplification of 5´ 
complementary DNA ends (5´-RACE) and primer extension, 
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we were able to identify complete structure of rat GLUT2 gene, 
which has four split exon 1 (1a to 1d). This discovery let us to 
obtain the rat GLUT2 promoter region, which conveys many 
potential transcription regulatory elements [2]. Next, we tried 
to find the mechanism of regulation of GLUT2 gene expression 
in liver. GLUT2 is a major glucose transporter in liver and pan-
creatic β-cells, and we initially focused to liver because nuclear 
extract from this organ is easier to prepare to study DNA-pro-
tein interaction, including DNase I footprinting and electro-
phoretic mobility shift assay (EMSA). The DNase I footprint-
ing assay was a difficult and laborious experiment and took a 
long time, but finally we demonstrated CCAAT/enhancer 
binding protein (C/EBP) elements in the GLUT2 promoter. 
Furthermore, it was also identified that the regulation by C/
EBPs were gradually attenuated in the primary cultured hepa-
tocytes, providing an evidence why primary hepatocytes on 
culture dishes lose their ability to express GLUT2 [3]. These 
earlier studies became foundation stone of my research. 
EXPANSION TO HUMAN GLUT2 PROMOTER
GLUT2 gene is mainly expressed in liver and pancreatic β- 
cells; however, the transcription factors and cis-elements regu-
lating the tissue-specific expression of the GLUT2 were largely 
unknown. Transfection studies using pancreatic β-cells (HIT-
T15, MIN6), hepatoma cell (HepG2), and fibroblast cells (NI-
H3T3, HeLa) revealed the differences in the promoter activi-
ties and site C (87 to 132) responsible for tissue-specific ex-
pression of the human GLUT2 gene [4]. We identified that 
both hepatocyte nuclear factor 1 (HNF1) and HNF3 function 
as transcriptional activators in GLUT2 gene expression. The 
GLUT2 mRNA level was well correlated with the status of 
HNF1 and HNF3 mRNA levels regardless of the origins or 
types of cells. Furthermore, we showed that the promoter ac-
tivity of the mutG construct containing the 103A→G muta-
tion, which was found in a Korean non-insulin-dependent dia-
betes mellitus (NIDDM) patients, was in part compensated by 
the binding of nuclear factor Y (NF-Y) instead of HNF1 or 
HNF3 [5].
NUCLEAR RECEPTOR AND GLUCOSE 
SENSOR REGULATION IN LIVER AND 
β-CELLS
In the late 1990s, peroxisome proliferator-activated receptor γ 
(PPARγ) was identified as a target for thiazolidinedione 
(TZD), the first insulin sensitizing agent [6]. Anti-diabetic ac-
tion of TZD was thought to be mediated by PPARγ in adipose 
tissues until we identified that TZD restores the GLUT2 ex-
pression in pancreatic β-cells of type 2 diabetes mellitus 
(T2DM) model mice. While searching for transcription factors 
regulating GLUT2 gene, we noticed the presence of PPARγ re-
sponse element (PPRE) in 5´ untranslated region of the GLUT2 
gene. Although PPARγ in β-cells is not abundant, TZD treat-
ment directly up-regulated PPARγ-dependent GLUT2 expres-
sion and restored glucose sensing ability of β-cell in diabetic 
condition [7]. Subsequently, we identified PPRE in β-cell spe-
cific glucokinase (βGck) promoter and showed its functional 
relevance in β-cells [8]. 
After that, we studied liver glucokinase (L-Gck) promoter, 
because we wanted to stay focused in the hepatic glucose sen-
sor in connection with glucose homeostasis. In liver, we were 
able to identify and characterize the role of PPARγ in the regu-
lation of L-Gck [9,10]. Next, we demonstrated the interrela-
tionship among PPARγ, liver X-receptor α (LXRα), sterol reg-
ulatory element binding protein-1c (SREBP-1c), and small 
heterodimer partner (SHP) in the regulation of hepatic gluco-
kinase expression [11]. 
SREBP-1c AND GLUCOSE METABOLISM
The regulation of hepatic glucose metabolism is important in 
glucose homeostasis and L-Gck plays a central role in this pro-
cess. L-Gck expression is known to be regulated by insulin and 
SREBP-1c was suggested to be a transcription factor that medi-
ates the action of insulin on Gck transcription in liver. Howev-
er, the mechanism how SREBP-1c induce hepatic GK expres-
sion in response to insulin is not well characterized. Using 
DNA-protein interactions techniques, we identified sterol reg-
ulatory elements (SREs) in rat L-Gck promoter and present ev-
idences that insulin increases the binding of SREBP-1c on L-
Gck promoter resulting in the increase of the L-Gck transcrip-
tion [12].
In 2004, we performed an experiment whether SREBP-1c 
could be a potential trans-acting factor regulating GLUT2 in 
liver. At that time, GLUT2 gene expression was not known to 
be regulated by insulin. And thus, SREBP-1c could not be a 
transcriptional coactivator of GLUT2 gene expression. Howev-
er, we observed that both GLUT2 and SREBP-1c gene expres-
sion were increased in hyperglycemic states. Moreover, we 
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demonstrated that SREBP-1c binding region (SRE) is present 
in the mouse GLUT2 promoter. With these data, we concluded 
that glucose-stimulated activation of GLUT2 gene expression 
might be induced by SREBP-1c in primary cultured hepato-
cytes. Adenoviral expression of the dominant negative form of 
SREBP-1c suppressed glucose-stimulated GLUT2 mRNA level 
in primary cultured hepatocytes [13].
We also showed regulatory mechanism of GLUT4 gene ex-
pression in adipocytes. With increased GLUT4 expression, 
mRNA levels of SREBP-1c in adipose tissue were proportion-
ally increased by refeeding. Insulin treatment increased mRNA 
levels of GLUT4 in adipose tissue. Because SREBP-1c gene ex-
pression is regulated by insulin, it is thought that GLUT4 
might be regulated by SREBP-1c. On this basis, we examined 
presence of a potential site binding SBREP-1c in the GLUT4 
promoter and found highly conserved SRE. Through this 
study, we published a paper entitled, “Insulin-mediated activa-
tion of human GLUT4 promoter is directly induced by SREBP-
1c in adipocytes” [14]. 
Subsequent to this study, we hypothesized that transcription 
factor E3 (TFE3) could be able to up-regulate Gck because 
TFE3 was shown to up-regulate genes of insulin signaling 
pathway [15]. Using adenoviral transduction of TFE3, we 
demonstrated the presence of TFE3 binding site (E-box) in the 
Gck and TFE3 up-regulates Gck with amelioration of hypergly-
cemia in the db/db and ob/ob mice [16]. Fig. 1 shows a sum-
mary of cis-elements and trans-acting factors acting on the 
glucose sensor genes in liver explored by my team.
ROLE OF PPARα AND PROLACTIN 
REGULATORY ELEMENT-BINDING ON THE 
GLUCONEOGENESIS
When glucose level is low, blood glucose level is maintained by 
hepatic gluconeogenesis. Because increase in a hepatic glucose 
production occurs in the post-absorptive state of T2DM, it is 
Fig. 1. Schematic summary of the regulation of liver type glucose transporter (glucose transporter type 2 [GLUT2]) and glucoki-
nase (Gck) promoter. During the long journey to understand glucose homeostasis, main interest of my group was how glucose 
sensors, GLUT2 and glucokinase, are regulated by transcription factors. Tissue-specific study, and disease-specific alteration as 
well, revealed that many transcriptional factors are interconnected in the regulation of glucose sensor in liver. C/EBP, CCAAT/
enhancer binding protein; PPARγ, peroxisome proliferator-activated receptor γ; RXRα, retinoid X receptor α; PPRE, PPARγ re-
sponse element; SREBP-1c, sterol regulatory element binding protein-1c; SRE, sterol regulatory element; HNF1α, hepatocyte nu-
clear factor 1 α; HNF, hepatocyte nuclear factor; FOXA2, forkhead box A2; LXRα, liver X-receptor α; SHP, small heterodimer 
partner; L-GcK, liver glucokinase; TFE3, transcription factor E3; LXRE, liver X-receptor response element.
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required to unveil the mechanisms of how hyperglycemia de-
velops. To explore a pathogenesis, we are interested in a role of 
PPARα and prolactin regulatory element-binding (PREB). 
First, we have performed experiments based on the previous 
observation that PPARα-null mice shows severe hypoglycemia 
following 24-hour fasting, characterized by a 50% drop in 
blood glucose level, suggesting a potential role of PPARα in 
glucose metabolism [17]. Using PPARα knockout (KO) mice 
as an animal model, we were able to demonstrate presence of 
PPRE and indicated that PPARα might be responsible for glu-
cose production through the regulation of hepatic G6pase ex-
pression [18]. Most recently, we observed that PREB protein is 
down-regulated in the liver of db/db, ob/ob, and high-fat diet-
induced obese mice. This observation led us to explore a possi-
bility that PREB could be a transacting factor down-regulating 
gluconeogenic. Indeed, we found a cis-element, prolactin core-
binding element in the promoters of gluconeogenic genes, 
which is responsible for down-regulation of these genes, that 
is, decreased PREB in the liver of insulin resistant animal can-
not repress the expression of gluconeogenic genes (G6Pase and 
phosphoenolpyruvate carboxykinase [Pck]), resulting in the 
hyperglycemia, a typical manifestation of the diabetic model 
mice or high fat induced obesity mice [19]. 
ROLE OF PROTEIN INTERACTIONS AND 
GLUCOSE HOMEOSTASIS 
Glucose homeostasis is of prime importance in maintaining 
whole body metabolism. In the insulin resistant states, a bal-
ance in the intermediary metabolism may be disturbed. Dur-
ing prolonged starvation, hepatic gluconeogenesis is a major 
pathway that maintains normal blood glucose levels. In the 
postprandial state, temporarily increased glucose needs to be 
disposed by liver to prevent the cells from glucotoxicity. In this 
process, Gck is known to play the most important role [20].
Although we have been stayed focus on the transcriptional 
aspects of metabolic genes in liver, we have also searched for 
the possibility that post-translational modification of metabol-
ic enzymes/protein could also be a novel regulatory mecha-
nism. Using current proteome technology, we were able to 
demonstrate that glucokinase regulatory protein (GKRP) in 
liver is acetylated by acetyltransferase p300. Acetylated GKRP 
decreases ubiquitination of the protein itself with an increase 
in its affinity to Gck, resulting in increased nuclear retention of 
Gck and decreased glycolytic flux [21]. 
To understand this, we have done couple of studies to eluci-
date mechanisms of how hepatic gluconeogenesis occurs. 
From the beginning, we showed that insulin-mediated repres-
sion of G6pase and Pck gene expression is restored by resvera-
trol, which might be associated with sirtuin 1 (Sirt1) mediated 
forkhead box O1 (FOXO1) deacetylation [22]. And then, we 
found a role of thioredoxin-interacting protein (TXNIP) in the 
hyperglycemia. The increased TXNIP in the hyperglycemic 
mice model, impairs glucose and insulin tolerance in mice by 
up-regulating G6pase through interaction with SHP. Binding 
of TXNIP to SHP resulted in the degradation of SHP through 
ubiquitination, allowing FOXO1 to up-regulate gluconeogenic 
gene expression [23].
ROLE OF CREB3L4 ON THE ADIPOGENESIS 
Another field of our research was transcriptional connections 
in adipogenesis. We were interested in obesity problem, which 
became a worldwide epidemic. To this end, we wanted to ex-
plore signaling networks governed by transcription factors in-
volved in the adipogenesis, ultimately to understand the patho-
physiology of obesity and T2DM. Using cyclic AMP-respon-
sive element-binding protein 3 (CREB3)-like 4 (CREB3L4) KO 
mice, we demonstrated that CREB3L4 acts as a negative regu-
lator of adipogenesis [24]. In this paper we demonstrated that 
CREB3L4 binds C/EBPβ, promoting its ubiquitination, result-
ing in the inhibition of adipogenesis and obesity in mice (Fig. 
2A). Thus, if a measure to trigger CREB3L4 expression is taken, 
it could be one of novel way to treat obesity or T2DM. In con-
nection with this work, we published a paper entitled, “The ef-
fects of low fat diet (LFD) or aging on the metabolic profiles of 
Creb3l4 KO mice,” which showed significant weight gain and 
adiposity with impaired glucose tolerance and decreased insu-
lin sensitivity in Creb3l4 KO mice [25]. Furthermore, we dem-
onstrated that CREB3L4 is required for proliferation of pros-
tate cancer cells and CREB3L4 is a crucial activator of andro-
gen receptor (AR) function. CREB3L4 directly interacts with, 
and facilitates, AR recruitment to the androgen responsive ele-
ments (AREs) of AR target genes. In addition, indirectly, 
through inositol requiring enzyme 1α signaling, a distinct AR-
endoplasmic reticulum stress-CREB3L4 regulatory axis also 
plays a role in prostate cancer proliferation (Fig. 2B) [26]. Table 
1 shows a summary of major works done by my team for the 
last 25 years. 
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Fig. 2. Role of cyclic AMP-responsive element-binding protein 3 (CREB3)-like 4 (CREB3L4) on the adipogenesis. (A) In preadi-
pocytes, CREB3L4 acts as a negative regulator of adipogenesis by both regulating the stability of CCAAT/enhancer binding pro-
tein β (C/EBPβ) protein and increasing GATA binding protein 3 (GATA3) expression. (B) Proposed mechanism of action of 
CREB3L4 in prostate cancer progression. Adapted from Kim et al. [24,26]. IBMX, 3-isobutyl-1-methylxanthine; AR, androgen 
receptor; IRE1α, inositol requiring enzyme 1α.
A B
Table 1. Summary of major research papers of my team
Year Journal Research subject Contributor(s)
1995 Arch Biochem Biophys L-GLUT2 promoter cloning Ahn et al. [2]
1998 Biochem J L-GLUT2 promoter, C/EBP Kim et al. [3]
2000 J Biol Chem L-GLUT2 liver specific expression, HNF1&3 Cha et al. [4]
2000 Diabetes L-GLUT2 promoter, PPRE Kim et al. [7]
2002 Diabetes Β-Glucokinase, PPARγ Kim et al. [8]
2004 Diabetes L-GcK promoter, PPARγ Kim et al. [10]
2004 J Biol Chem L-GcK promoter, SREBP-1c Kim et al. [12]
2005 Diabetes L-GLUT2 promoter, SREBP-1c Im et al. [13]
2006 Biochem J GLUT4 promoter, SREBP-1c adipocytes Im et al. [14]
2009 J Biol Chem L-GcK promoter, LXR, SREBP-1c, PPARγ Kim et al. [11]
2011 J Biol Chem G6Pase promoter, PPARα Im et al. [18]
2013 Diabetologia L-GcK gene, TFE3 Kim et al. [16]
2013 Diabetologia Liver gluconeogenic gene, Txnip Jo et al. [23]
2014 Cell Death Dis Adipogenesis and CREB3L4 Kim et al. [24]
2015 Sci Rep L-GcK and GKRP acetylation Park et al. [21]
2017 Sci Rep Prostate cancer and CREB3L4 Kim et al. [26]
2018 BBA Mol Basis Dis Liver PREB and glucose homeostasis Park et al. [19]
L-GLUT2, liver-glucose transporter type 2; C/EBP, CCAAT/enhancer binding protein; HNF, hepatocyte nuclear factor; PPRE, PPARγ response 
element; PPAR, peroxisome proliferator-activated receptor; L-GcK, liver glucokinase; SREBP-1c, sterol regulatory element binding protein-1c; 
LXR, liver X-receptor; G6Pase, glucose-6-phosphatase; TFE3, transcription factor E3; CREB3L4, cyclic AMP-responsive element-binding pro-
tein 3 (CREB3)-like 4; GKRP, glucokinase regulatory protein; PREB, prolactin regulatory element-binding.
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SUMMARY
My team has been exploring the roles of transcription factors 
regulating the genes involved in glucose metabolism for the 
last 30 years. The main field of study can be summarized as (1) 
identification of promoters of genes of glucose homeostasis, (2) 
exploration of interaction between promoters and transcrip-
tion factors leading to tissue-specific gene expression, (3) 
modification and interactions between transcription factors in 
metabolic diseases such as diabetes or obesity, and (4) role of a 
transcription factor in the adipocyte differentiation and devel-
opment of obesity. While studying transcriptional regulation, 
my team members were interconnected as if we were tran-
scription factors coordinating with each other. As an analogy, I 
might act as a basal transcription factor and my team-mates, 
wherever they are, played co-activator role. Without their de-
votion in science, the works of my group could not be made 
possible. 
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